Display options
Share it on

J Magn Reson Imaging. 2021 Oct 20; doi: 10.1002/jmri.27962. Epub 2021 Oct 20.

A New Reporting System for Diagnosis of Hepatocellular Carcinoma in Chronic Hepatitis B With Clinical and Gadoxetic Acid-Enhanced MRI Features.

Journal of magnetic resonance imaging : JMRI

Shin Hye Hwang, Seung Baek Hong, Kyunghwa Han, Nieun Seo, Jin-Young Choi, Jei Hee Lee, Sumi Park, Young-Suk Lim, Do Young Kim, So Yeon Kim, Mi-Suk Park

Affiliations

  1. Department of Radiology, Yongin Severance Hospital, Yongin, Gyeonggi-do, South Korea.
  2. Department of Radiology, Biomedical Research Institute, Pusan National University Hospital, and Pusan National University School of Medicine, Pusan, South Korea.
  3. Department of Radiology, Asan Medical Center, Ulsan University College of Medicine, Seoul, South Korea.
  4. Department of Radiology and Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
  5. Department of Radiology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
  6. Department of Radiology, Ajou University Hospital, Suwon, South Korea.
  7. Department of Radiology, National Health Insurance Service Ilsan Hospital, Goyang, South Korea.
  8. Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  9. Department of Internal Medicine, Severance Hospital, Seoul, South Korea.

PMID: 34668595 DOI: 10.1002/jmri.27962

Abstract

BACKGROUND: Current major guidelines for diagnosis of hepatocellular carcinoma (HCC) based on imaging findings are different from each other and do not include clinical risk factors as a diagnostic criteria.

PURPOSE: To developed and validated a new diagnostic score system using MRI and clinical features as applied in chronic hepatitis B patients.

STUDY TYPE: Retrospective observational study.

SUBJECT: A total of 418 treatment-naïve patients (out of 902 patients) with chronic hepatitis B having 556 lesions suspected for HCC which were eligible for curative treatment.

FIELD STRENGTH/SEQUENCE: T1W GRE in- and opposed-phase, T2W FSE, DWI, and T1W 3D-GRE dynamic contrast-enhanced sequences at 1.5  T and 3  T.

ASSESSMENT: Six radiologists with 7-22 years of experience independently evaluated MR images based on Liver Imaging Reporting and Data System (LI-RADS) version 2018.

STATISTICAL TESTS: Based on logistic regression analysis of MRI features and clinical factors, a risk score system was devised in derivation cohorts (268 patients, 352 lesions) and externally validated (150 patients, 204 lesions). The performance of the new score system was assessed by Harell's c-index. Using cutoff value of 12, maintaining positive predictive value ≥95%, the diagnostic performances of the score system were compared with those of LR-5.

RESULTS: The 15-point diagnostic scoring system used MRI features (lesion size, nonrim arterial phase hyperenhancement, portal venous phase hypointensity, hepatobiliary phase hypointensity, and diffusion restriction) and clinical factors (alpha-fetoprotein and platelet). It showed good discrimination in the derivation (c-index, 0.946) and validation cohorts (c-index, 0.907). Using a risk score of 12 as a cut-off, this system yielded higher sensitivity than LR-5 (derivation cohort, 76.8% vs. 52.1%; validation cohort, 73.4% vs. 49.5%) without significant decrease in specificity (derivation cohort, 93.1% vs. 97.2%, P = 0.074; validation cohort, 91.7% vs. 96.1%, P = 0.299).

DATA CONCLUSION: A new score system showed improved sensitivity in chronic hepatitis B patients compared to LI-RADS without significant compromise in specificity. EVIDENCE LEVEL: 3 TECHNICAL EFFICACY: Stage 2.

© 2021 International Society for Magnetic Resonance in Medicine.

Keywords: carcinoma; diagnosis; gadolinium DTPA; hepatocellular; magnetic resonance imaging

References

  1. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723-750. - PubMed
  2. EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236. - PubMed
  3. Lee YJ, Lee JM, Lee JS, et al. Hepatocellular carcinoma: Diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 2015;275:97-109. - PubMed
  4. Hanna RF, Miloushev VZ, Tang A, et al. Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol (NY) 2016;41:71-90. - PubMed
  5. Renzulli M, Biselli M, Brocchi S, et al. New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: A new diagnostic algorithm. Gut 2018;67:1674-1682. - PubMed
  6. Velázquez RF, Rodríguez M, Navascués CA, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003;37:520-527. - PubMed
  7. Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): Development and validation of a predictive score. Lancet Oncol 2011;12:568-574. - PubMed
  8. Flemming JA, Yang JD, Vittinghoff E, Kim WR, Terrault NA. Risk prediction of hepatocellular carcinoma in patients with cirrhosis: The ADRESS-HCC risk model. Cancer 2014;120:3485-3493. - PubMed
  9. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. Eur Urol 2015;67:1142-1151. - PubMed
  10. The Korean Association for the Study of the L. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol 2012;18:109-162. - PubMed
  11. Theise NDCM, Franceschi S. Hepatocellular carcinoma. In: CF BFT, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. Lyon: International Aagency of Research on Cancer; 2010. p 205-216. - PubMed
  12. van der Pol CB, Lim CS, Sirlin CB, et al. Accuracy of the liver imaging reporting and data system in computed tomography and magnetic resonance image analysis of hepatocellular carcinoma or overall malignancy-a systematic review. Gastroenterology 2019;156:976-986. - PubMed
  13. Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 2016;64:800-806. - PubMed
  14. Chan SL, Mo F, Johnson PJ, et al. Performance of serum alpha-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. HPB (Oxford) 2014;16:366-372. - PubMed
  15. Gopal P, Yopp AC, Waljee AK, et al. Factors that affect accuracy of alpha-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014;12:870-877. - PubMed
  16. Ahn DG, Kim HJ, Kang H, et al. Feasibility of alpha-fetoprotein as a diagnostic tool for hepatocellular carcinoma in Korea. Korean J Intern Med 2016;31:46-53. - PubMed
  17. Shin Y, Kim KW, Lee AJ, et al. A good Practice-compliant clinical trial imaging management system for multicenter clinical trials: Development and validation study. JMIR Med Inform 2019;7:e14310. - PubMed
  18. Tang A, Bashir MR, Corwin MT, et al. Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: A systematic review. Radiology 2018;286:29-48. - PubMed
  19. Chernyak V, Fowler KJ, Kamaya A, et al. Liver imaging reporting and data system (LI-RADS) version 2018: Imaging of hepatocellular carcinoma in at-risk patients. Radiology 2018;289:816-830. - PubMed
  20. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174. - PubMed
  21. Fleiss JL, Cohen J. The equivalence of weighted kappa and the Intraclass correlation coefficient as measures of reliability. Educ Psychol Meas 1973;33:613-619. - PubMed
  22. Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010;138:493-502. - PubMed
  23. Sullivan LM, Massaro JM, D'Agostino RB. Presentation of multivariate data for clinical use: The Framingham study risk score functions. Stat Med 2004;23:1631-1660. - PubMed
  24. Barili F, Pacini D, Grossi C, Di Bartolomeo R, Alamanni F, Parolari A. Reliability of new scores in predicting perioperative mortality after mitral valve surgery. J Thorac Cardiovasc Surg 2014;147:1008-1012. - PubMed
  25. Kim JH, Kim YD, Lee M, et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. J Hepatol 2018;69:1066-1073. - PubMed
  26. Lee HW, Kim SU, Park JY, et al. External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy. Liver Int 2019;39:1624-1630. - PubMed
  27. Zhang J, Chen G, Zhang P, et al. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One 2020;15:e0228857. - PubMed
  28. Lee S, Kim SS, Chang DR, Kim H, Kim MJ. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. Clin Mol Hepatol 2020;26:340-351. - PubMed
  29. Kim DH, Choi SH, Kim SY, Kim MJ, Lee SS, Byun JH. Gadoxetic acid-enhanced MRI of hepatocellular carcinoma: Value of washout in transitional and hepatobiliary phases. Radiology 2019;292:270. - PubMed
  30. Joo I, Lee JM, Lee DH, Jeon JH, Han JK. Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features? Eur Radiol 2019;29:1724-1732. - PubMed
  31. Piana G, Trinquart L, Meskine N, Barrau V, Beers BV, Vilgrain V. New MR imaging criteria with a diffusion-weighted sequence for the diagnosis of hepatocellular carcinoma in chronic liver diseases. J Hepatol 2011;55:126-132. - PubMed
  32. Korean Society of Abdominal Radiology. Diagnosis of hepatocellular carcinoma with gadoxetic acid-enhanced MRI: 2016 consensus recommendations of the Korean Society of Abdominal Radiology. Korean J Radiol 2017;18:427-443. - PubMed
  33. Carr BI, Guerra V. Thrombocytosis and hepatocellular carcinoma. Dig Dis Sci 2013;58:1790-1796. - PubMed
  34. Carr BI, Guerra V, Giannini EG, et al. Significance of platelet and AFP levels and liver function parameters for HCC size and survival. Int J Biol Markers 2014;29:e215-e223. - PubMed
  35. Akkiz H, Carr BI, Yalçın KK, et al. Characteristics of hepatocellular carcinoma aggressiveness factors in Turkish patients. Oncology 2018;94:116-124. - PubMed
  36. Carr BI, Pancoska P, Giannini EG, et al. Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters. Semin Oncol 2014;41:406-414. - PubMed

Publication Types